» Articles » PMID: 20121196

Discovery of Novel Fibroblast Growth Factor Receptor 1 Kinase Inhibitors by Structure-based Virtual Screening

Overview
Journal J Med Chem
Specialty Chemistry
Date 2010 Feb 4
PMID 20121196
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Fibroblast growth factors (FGFs) play important roles in embryonic development, angiogenesis, wound healing, and cell proliferation and differentiation. In search of inhibitors of FGFR1 kinase, 2.2 million compounds were docked into the ATP binding site of the protein. A co-crystal structure, which shows two alternative conformations for the nucleotide binding loop, is reported. Docking was performed on both conformations and, ultimately, 23 diverse compounds were purchased and assayed. Following hit validation, two compounds 10 and 16, a benzylidene derivative of pseudothiohydantoin and a thienopyrimidinone derivative, respectively, were discovered that inhibit FGFR1 kinase with IC(50) values of 23 and 50 microM. Initial optimization of 16 led to the more unsaturated 40, which has significantly enhanced potency, 1.9 microM. The core structures represent new structural motifs for FGFR1 kinase inhibitors. The study also illustrates complexities associated with the choice of protein structures for docking, possible use of multiple kinase structures to seek selectivity, and hit identification.

Citing Articles

The role of GZMA as a target of cysteine and biomarker in Alzheimer's disease, pelvic organ prolapse, and tumor progression.

Li Y, Wang Z, Kong M, Yong Y, Yang X, Liu C Front Pharmacol. 2024; 15:1447605.

PMID: 39228516 PMC: 11368878. DOI: 10.3389/fphar.2024.1447605.


Alkoxyalkylation of Electron-Rich Aromatic Compounds.

Simon P, Lorinczi B, Szatmari I Int J Mol Sci. 2024; 25(13).

PMID: 39000077 PMC: 11241777. DOI: 10.3390/ijms25136966.


Applications of machine learning in computer-aided drug discovery.

Turzo S, Hantz E, Lindert S QRB Discov. 2023; 3:e14.

PMID: 37529294 PMC: 10392679. DOI: 10.1017/qrd.2022.12.


A Guide to In Silico Drug Design.

Chang Y, Hawkins B, Du J, Groundwater P, Hibbs D, Lai F Pharmaceutics. 2023; 15(1).

PMID: 36678678 PMC: 9867171. DOI: 10.3390/pharmaceutics15010049.


Absolute binding free energy calculations improve enrichment of actives in virtual compound screening.

Feng M, Heinzelmann G, Gilson M Sci Rep. 2022; 12(1):13640.

PMID: 35948614 PMC: 9365818. DOI: 10.1038/s41598-022-17480-w.


References
1.
Hennequin L, Allen J, Breed J, Curwen J, Fennell M, Green T . N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem. 2006; 49(22):6465-88. DOI: 10.1021/jm060434q. View

2.
Rubin J, Humblet C, Hamby J, Showalter H . Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J Med Chem. 1998; 41(11):1752-63. DOI: 10.1021/jm970634p. View

3.
Singh J, Chuaqui C, Boriack-Sjodin P, Lee W, Pontz T, Corbley M . Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorg Med Chem Lett. 2003; 13(24):4355-9. DOI: 10.1016/j.bmcl.2003.09.028. View

4.
Webster M, dAvis P, Robertson S, Donoghue D . Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol. 1996; 16(8):4081-7. PMC: 231404. DOI: 10.1128/MCB.16.8.4081. View

5.
Noble M, Endicott J, Johnson L . Protein kinase inhibitors: insights into drug design from structure. Science. 2004; 303(5665):1800-5. DOI: 10.1126/science.1095920. View